- Home
- ATNI vs ENGN Comparison
ATNI vs ENGN Comparison
Compare ATNI & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATNI | ENGN |
|---|---|---|
| Founded | 1987 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 337.6M | 605.5M |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATNI | ENGN |
|---|---|---|
| Price | $22.70 | $9.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.71 |
| AVG Volume (30 Days) | 53.6K | ★ 245.0K |
| Earning Date | 11-05-2025 | 12-22-2025 |
| Dividend Yield | ★ 4.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $724,308,000.00 | N/A |
| Revenue This Year | $1.77 | N/A |
| Revenue Next Year | $2.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.76 | $2.65 |
| 52 Week High | $23.76 | $11.14 |
Technical Indicators
Market Signals| Indicator | ATNI | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 62.13 | 58.22 |
| Support Level | $21.93 | $7.57 |
| Resistance Level | $23.76 | $9.81 |
| Average True Range (ATR) | 0.68 | 0.72 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 56.50 | 60.47 |
Price Performance
Historical ComparisonAbout ATNI ATN International Inc.
ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.